Drug Trial Radar · NCT00960661
A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes
Last checked: Nov 20, 2026Latest source record: Apr 7, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,036
Actual
Start
Sep 2009
Primary completion
Aug 2012
Study completion Aug 2012
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Eli Lilly and Company
- First posted
- Aug 18, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will compare two combination therapies: 1) Combined Basal Insulin Glargine (once a day), Exenatide (twice a day), and Metformin Therapy; or 2) Combined Basal Insulin Glargine (once a day), Bolus Insulin Lispro (three times a day), and Metformin Therapy, in subjects with Type 2 Diabetes Mellitus who have inadequate glycemic control.
Conditions
- Type 2 Diabetes Mellitus
Interventions
exenatideDrug
subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (26 weeks), twice a day
insulin lisproDrug
titrated based on pre-meal glucose level; three times a day
MetforminDrug
Insulin/ GlargineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 30Time frame: Baseline, 30 weeks
Locations
95 sites in 18 countries. Site status is shown where the registry gives one.
Research Site
Buenos Aires, Argentina
Research Site
Caba, Argentina
Research Site
Capital Federal, Argentina
Research Site
Ciudad Autonoma de Buenos Aire, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Corrientes, Argentina
Research Site
Rosario, Argentina
Research Site
San Rafael, Argentina
Research Site
Arlon, Belgium
Research Site
Bonheiden, Belgium
Research Site
Edegem, Belgium
Research Site
Merksem, Belgium
Research Site
Tallinn, Estonia
Research Site
Tartu, Estonia
Research Site
Helsinki, Finland
Research Site
Oulu, Finland
Research Site
Vantaa, Finland
Research Site
Angers, France
Research Site
Auxerre, France
Research Site
Bar-le-Duc, France
Research Site
Douai, France
Research Site
La Roche-sur-Yon, France
Research Site
La Rochelle, France
Research Site
Le Creuzot, France
Research Site
Lille, France
Research Site
Marseille, France
Research Site
Montpellier, France
Research Site
Nanterre, France
Research Site
Pessac, France
Research Site
Rennes, France
Research Site
Strasbourg, France
Research Site
Toulouse, France
Research Site
Vénissieux, France
Research Site
Bad Lauterberg im Harz, Germany
Research Site
Dippoldiswalde, Germany
Research Site
Friedrichsthal, Germany
Research Site
Goch, Germany
Research Site
Grevenbroich, Germany
Research Site
Hamburg, Germany
Research Site
Mainz, Germany
Showing 40 of 95 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.